The sclerostin monoclonal antibody (Scl-Ab/ Romosozumab), which inhibits the function of sclerostin and enhances bone formation (anabolic compound), is the most recent addition to the osteoporosis set of medications. This evidence concerns the gene SOST and osteoporosis.